CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03177239
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.853072+00:00
Published At: 2022-02-16T00:00:00+00:00
Record Updated At: 2022-02-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma Type 1", "Papillary Renal Cell Carcinoma Type 2", "Chromophobe Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Xp11 Translocation Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-16"
protocolSection.identificationModule.nctId: "NCT03177239"
protocolSection.identificationModule.officialTitle: "A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)."
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.